Enhancera: Empowering Antibiotic Efficacy

Enhancera revolutionizes antibiotic efficacy through potentiation, targeting bacterial mechanisms to overcome resistance. Our approach enhances antibiotic potency, broadening effectiveness against gram-negative infections. By prioritizing surface-targeting mechanisms, we mitigate penetration challenges. Enhancera offers a novel strategy in the fight against antimicrobial resistance.

Nasma Hamoud, CEO of Enhancera, leads our team in revolutionizing antibiotic efficacy through potentiation. With a background in microbiology, Nasma  dedicated to combating antimicrobial resistance and improving global health outcomes.

Enhancera addresses the pressing challenge of antimicrobial resistance (AMR), a global health threat affecting millions worldwide. Current estimates attribute 4.95 million deaths annually to AMR, with projections indicating a rise to 10 million deaths per year by 2050. The problem is particularly acute in low- and middle-income communities where access to effective antibiotics is limited, exacerbating the spread of resistant bacteria.

Enhancera's innovative potentiation approach targets bacterial mechanisms to enhance antibiotic efficacy, offering a solution to overcome AMR. By broadening the spectrum of antibiotics and increasing potency against gram-negative infections, Enhancera aims to mitigate the impact of AMR on global health. Our solution addresses the root cause of AMR by enhancing antibiotic effectiveness, reducing the reliance on traditional antibiotics, and providing a novel strategy to combat resistance. Through this approach, Enhancera aims to protect communities worldwide from the devastating consequences of antimicrobial resistance.

Enhancera's solution serves a diverse range of stakeholders involved in healthcare, including healthcare providers, patients, and public health agencies, particularly in low- and middle-income communities where the burden of antimicrobial resistance (AMR) is most severe. Our solution addresses the critical need for effective antibiotics by enhancing their potency and broadening their spectrum of activity against resistant bacteria.

We engage with healthcare providers and public health agencies to understand the challenges they face in managing antibiotic-resistant infections and the limitations of existing treatment options. Through partnerships and collaborations, we gather insights into the specific needs and priorities of different communities, allowing us to tailor our research and development efforts to address these needs effectively.

By developing innovative potentiation approaches, Enhancera aims to provide healthcare providers with more effective tools to combat AMR and improve patient outcomes. Ultimately, our solution seeks to support healthcare systems in their efforts to manage and mitigate the impact of antimicrobial resistance on global health.

Enhancera's solution provides several public goods to benefit the well-being of the public:

1. Open Access Research: We commit to publishing our research findings in peer-reviewed journals, making our discoveries and insights accessible to the scientific community worldwide. This dissemination of knowledge contributes to the collective understanding of antimicrobial resistance (AMR) and supports global efforts to combat this public health threat.

2. Collaborative Partnerships: Enhancera actively engages with public health agencies, academic institutions, and non-profit organizations to share our expertise and collaborate on initiatives aimed at addressing AMR. By fostering collaboration and knowledge-sharing, we facilitate collective action to mitigate the impact of AMR on global health.

3. Training and Capacity Building: We offer training programs and capacity-building initiatives to empower healthcare professionals and researchers with the knowledge and skills needed to combat AMR effectively. By investing in human capital development, we contribute to strengthening healthcare systems and improving patient outcomes worldwide.

Enhancera's solution will create tangible impact by enhancing antibiotic efficacy and combating antimicrobial resistance (AMR) for our target population, which includes healthcare providers, patients, and public health agencies in low- and middle-income communities.

By developing potentiation approaches to enhance antibiotic effectiveness, Enhancera will provide healthcare providers with more effective tools to combat resistant infections, ultimately improving patient outcomes and reducing the burden of AMR on healthcare systems. Our solution will broaden the spectrum of antibiotics and increase their potency against resistant bacteria, addressing a critical need in communities where access to effective antibiotics is limited.

Through collaborative partnerships and open access research, Enhancera will contribute to the collective understanding of AMR and support global efforts to combat this public health threat. By empowering healthcare professionals with training and capacity-building initiatives, we will strengthen healthcare systems and improve patient care for underserved populations worldwide.

Over the next year, Enhancera will focus on advancing our potentiation approaches from the Proof of Concept stage to pilot testing in real-world settings. We will collaborate with healthcare providers and public health agencies to conduct pilot studies and evaluate the effectiveness of our potentiation strategies in clinical settings. Additionally, we will continue to strengthen our partnerships with pharmaceutical companies and research institutions to accelerate the development and optimization of our potentiation approaches.

Over the next three years, Enhancera aims to scale our impact by expanding our pilot initiatives to multiple communities and regions affected by antimicrobial resistance (AMR). We will work towards regulatory approval and commercialization of our potentiation approaches, ensuring widespread access to effective antibiotics for underserved populations. Additionally, we will continue to invest in research and development to identify new potentiation mechanisms and enhance the efficacy of existing strategies. Through these efforts, Enhancera seeks to make a transformative impact on society by combating AMR and improving global health outcomes.

Enhancera measures success against our impact goals through several key indicators:

1. Reduction in Antibiotic Resistance: We track the prevalence of antibiotic-resistant infections in pilot communities to assess the impact of our potentiation approaches on reducing resistance rates. A 10% decrease in resistance rates within the pilot population will be considered a significant success.

2. Improved Patient Outcomes: We monitor clinical outcomes, including infection recurrence rates, hospitalization rates, and mortality rates, to evaluate the effectiveness of our potentiation strategies in improving patient outcomes. A 20% decrease in hospitalization rates and a 15% decrease in mortality rates among patients treated with potentiated antibiotics will indicate success.

3. Healthcare Provider Adoption: We measure the adoption rate of our potentiation approaches by healthcare providers in pilot settings. A 50% increase in the number of healthcare providers prescribing potentiated antibiotics over the course of the pilot will demonstrate successful adoption and integration into clinical practice.

Through ongoing monitoring and evaluation, Enhancera will assess progress towards our impact goals and refine our approach to maximize effectiveness in combating antimicrobial resistance and improving global health outcomes.

In the next three years, Enhancera plans to deploy our solution in Kenya, Rwanda, and Uganda, where the burden of antimicrobial resistance (AMR) is significant, and there is a pressing need for innovative approaches to combat this challenge. These countries have relatively strong healthcare infrastructure, supportive policy environments, and active public health agencies, facilitating the rapid scaling of our solution.

Barriers to accomplishing our goals include regulatory approval processes, financial constraints, and cultural barriers. We plan to overcome these barriers by engaging with regulatory authorities to streamline approval processes, securing funding through grants and partnerships, and conducting community outreach and education programs to raise awareness about the importance of combating AMR.

Additionally, we will leverage our partnerships with local healthcare providers, research institutions, and non-profit organizations to navigate cultural and logistical challenges and ensure the successful implementation and adoption of our solution in target environments. Through these efforts, we aim to overcome barriers and maximize our impact on combating AMR in East Africa.

We are applying to The Trinity Challenge because it offers a unique opportunity to address the barriers we face in combatting antimicrobial resistance (AMR). Specifically, The Trinity Challenge can help us overcome challenges related to access to funding, regulatory compliance, and stakeholder engagement. Through The Trinity Challenge's network of partners and resources, we can access additional funding to support our research and development efforts, navigate complex regulatory approval processes more efficiently, and engage with key stakeholders to gather insights and support for our solution. Furthermore, The Trinity Challenge's focus on collaboration and innovation aligns closely with our mission, providing a platform to amplify our impact and contribute to global efforts in addressing AMR effectively.

What organization(s) would you like to collaborate with to initiate, accelerate, or scale your solution?You can highlight specific organizations or a broader field of expertise that would benefit your solution. How will this help you? The Challenge is supported by a dedicated group of collaborators who offer mentoring and other resources to solutions - please see the FAQs tab for more information.
Maximum 200 words